Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 53.22 -2.71% -1.48
PTLA closed down 2.71 percent on Thursday, August 17, 2017, on 47 percent of normal volume. It ran into resistance at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical PTLA trend table...

Date Alert Name Type % Chg
Aug 17 50 DMA Resistance Bearish 0.00%
Aug 16 Fell Below 50 DMA Bearish -2.71%
Aug 15 Lower Bollinger Band Walk Other -3.25%
Aug 15 MACD Bearish Centerline Cross Bearish -3.25%
Aug 14 Lower Bollinger Band Walk Other -3.38%

Older signals for PTLA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 67.1
52 Week Low 15.68
Average Volume 1,167,611
200-Day Moving Average 36.5217
50-Day Moving Average 55.082
20-Day Moving Average 60.569
10-Day Moving Average 57.289
Average True Range 2.4234
ADX 34.31
+DI 12.35
-DI: 27.49
Chandelier Exit (Long, 3 ATRs) 59.8298
Chandelier Exit (Short, 3 ATRs) 60.4502
Upper Bollinger Band 68.8267
Lower Bollinger Band 52.3113
Percent B (%b) 0.06
Bandwidth 0.272671
MACD Line -0.8488
MACD Signal Line 0.6139
MACD Histogram -1.4627